Compile Data Set for Download or QSAR
Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 10698
TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560573(US11384048, Compound 13)
Affinity DataIC50: 13nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560576(US11384048, Compound 16)
Affinity DataIC50: 13nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560575(US11384048, Compound 15)
Affinity DataIC50: 14nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560435(US11384048, Compound 1)
Affinity DataIC50: 14nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560587(US11384048, Compound 27)
Affinity DataIC50: 18nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560580(US11384048, Compound 20)
Affinity DataIC50: 18nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560589(US11384048, Compound 29 | US20230331675, Compound ...)
Affinity DataIC50: 19nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560574(US11384048, Compound 14)
Affinity DataIC50: 19nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560577(US11384048, Compound 17)
Affinity DataIC50: 20nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560586(US11384048, Compound 26 | US11384048, Compound 30)
Affinity DataIC50: 20nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560447(US11384048, Compound 5)
Affinity DataIC50: 23nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560572(US11384048, Compound 12)
Affinity DataIC50: 24nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560592(US11384048, Compound 32)
Affinity DataIC50: 24nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560583(US11384048, Compound 23)
Affinity DataIC50: 26nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560586(US11384048, Compound 26 | US11384048, Compound 30)
Affinity DataIC50: 27nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560588(US11384048, Compound 28 | US11384048, Compound 31)
Affinity DataIC50: 29nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560588(US11384048, Compound 28 | US11384048, Compound 31)
Affinity DataIC50: 41nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560570(US11384048, Compound 8)
Affinity DataIC50: 42nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560582(US11384048, Compound 22)
Affinity DataIC50: 44nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560578(US11384048, Compound 18)
Affinity DataIC50: 46nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560444(US11384048, Compound 3)
Affinity DataIC50: 46nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560571(US11384048, Compound 9)
Affinity DataIC50: 57nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560579(US11384048, Compound 19)
Affinity DataIC50: 61nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560585(US11384048, Compound 25)
Affinity DataIC50: 66nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560581(US11384048, Compound 21)
Affinity DataIC50: 85nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560594(US11384048, Compound 34)
Affinity DataIC50: 180nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560593(US11384048, Compound 33)
Affinity DataIC50: 230nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560448(US11384048, Compound 6)
Affinity DataIC50: 320nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560584(US11384048, Compound 24)
Affinity DataIC50: 430nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560603(US11384048, Compound 43 | (S,E)-3-hydroxy-2-methyl...)
Affinity DataIC50: 540nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560601(US11384048, Compound 41 | (S,E)-3-hydroxy-2-methyl...)
Affinity DataIC50: 540nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560600(US11384048, Compound 40 | (S,E)-3-hydroxy-2-methyl...)
Affinity DataIC50: 580nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560602(US11384048, Compound 42 | (S,E)-3-hydroxy-2-methyl...)
Affinity DataIC50: 880nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560595(US11384048, Compound 35)
Affinity DataIC50: 1.10E+3nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560597(US11384048, Compound 37)
Affinity DataIC50: 1.30E+3nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560527(US11384048, Compound 7)
Affinity DataIC50: 1.40E+3nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560599(US11384048, Compound 39 | (S,E)-3-hydroxy-2-methyl...)
Affinity DataIC50: 2.20E+3nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560437(US11384048, Compound 2)
Affinity DataIC50: 3.10E+3nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560598(US11384048, Compound 38 | (S,E)-2-(3-(3-(benzo[d]i...)
Affinity DataIC50: 1.00E+4nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM560596(US11384048, Compound 36)
Affinity DataIC50: 1.00E+4nMAssay Description:Experimental Procedure1. The compound was formulated to 10 concentrations with a three-fold concentration gradient with 100% DMSO.2. The solution of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2022
Entry Details
US Patent